Immuno-oncology services scaled from discovery to clinical development

Definiens combines AI-based computational pathology with translational research to deliver robust biological insights. Whether you are investigating novel predictive biomarkers, developing an IO assay, performing a retrospective study, or looking for a CDx to support clinical trials, Definiens has the technology, experience, and quality to accelerate your clinical immuno-oncology portfolio.

Development stage-specific solutions

Tumor Landscape

Gain insights into the tumor microenvironment
Explore

Gain clear insights to move ahead with a potential therapy

  • Determine the expression pattern of a given biomarker in a tumor population
  • Identify the indications to pursue in your next (basket) trial
Definiens prevalence analysis finds the distribution across multiple indications or subgroups

Target Validation

Determine the presence of your target drugs
Explore

Get clear quantitative results to move ahead with your compound

  • Determine how the target is distributed in this indication
  • Identify which indication and sub-population will be best suited for this compound
Definiens biomarker analysis finds the presence and distribution of your drug target

Mode of Action

Confirm your drug's therapeutic performance
Explore

Confirm your drug’s therapeutic performance

  • Make sure that the pathway is affected as predicted
  • Determine the biomarker response before and after treatment
Definiens biomarker image analysis measures the biological response before and after treatment

Retrospective Signature Discovery

Develop biomarker signatures based on retrospective study results
Explore

Develop biomarker signatures based on retrospective study results

  • Determine the minimal feature set, the algorithm, and cutoff to best stratify patient sets into responders and non-responders
Definiens biomarker signature development process delivers concise stratification data with regulatory documentation

Prospective Patient Stratification Development

Streamline clinical trial strategy
Explore

Streamline clinical trial strategy using the right patient population

  • Stratify patients based on the IO biomarker signature
Definiens finds the right partner for assay analysis development, manages FDA submission, and delivers regulated documentation for analysis from discovery through late clinical phase

Diagnostic Development

Streamline diagnostic development strategy
Explore

Streamline diagnostic development strategy

  • Determine if your assay is sufficiently robust to be used as a diagnostic
  • Transfer the assay to a diagnostic
Definiens finds the right partner for assay analysis development, manages FDA submission, and delivers regulated documentation for analysis from discovery through late clinical phase

Quick insights into complex biology

Assay Analysis

Develop a robust biomarker assay
Explore

Develop a robust biomarker assay

  • Determine if your assay can be used or optimized for quantitative pathology
  • Compare the assay to other DNA or RNA assays
Definiens image analysis platform compares assay candidates and omics data

Inter-study Comparison

Identify trends to generate hypotheses
Explore

Compare results across studies

  • Compare similar biomarker sets across studies to generate hypotheses from biological (dis-)similarities
  • Determine if old data/findings can be worked into new projects
Definiens standardized image analysis platform is ideal for cross-study comparisons

Ready to learn more about Definiens Solutions? Contact us today.